Abbott Vascular's Absorb Bioresorbable Vascular Scaffold Approved in Japan


November 7, 2016—Abbott Vascular announced Japan’s Ministry of Health, Labor, and Welfare has approved the company’s Absorb bioresorbable coronary stent. Sold commercially as the Absorb GT1 bioresorbable vascular scaffold system, the device was recently approved in the United States and Canada, and has been used in more than 100 countries.

Japanese approval of the device was supported by results of the ABSORB JAPAN clinical trial. Prof. Takeshi Kimura, MD, Director of Cardiovascular Medicine at Kyoto University Hospital in Kyoto, Japan, is principal investigator of ABSORB JAPAN. In the company’s press release, Dr. Kimura commented, “Absorb has the potential to address the unsolved challenges of managing coronary artery disease with conventional drug-eluting metallic stents. Our research, which involved 400 patients at 38 Japanese sites, shows that this fully dissolving stent delivered comparable results to the best-in-class Abbott Xience metallic drug-eluting stent on clinically important measures of safety and efficacy.”


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007, with its launch issue focusing on the state of coronary drug-eluting stent use. Each edition will cover a variety of topics in a flexible format that includes articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's cardiology practices.